Pfizer to discontinue weight loss pill’s twice-daily dosage variant
Pfizer announced on Friday that it will stop pursuing the twice-daily version of its experimental weight loss pill after obese patients in a mid-stage clinical study reported significant weight loss but had difficulty tolerating the drug due to high rates of mild and gastrointestinal side effects. The pharmaceutical giant’s decision comes after it observed that…